Description

PENTRAL 400MG (1X15)

Indications

PENTRAL 400MG is primarily indicated for the treatment of various neurological disorders, including epilepsy and neuropathic pain. It is often prescribed to manage seizures in patients with epilepsy and to alleviate chronic pain conditions that arise from nerve damage. The medication may also be utilized in the management of anxiety disorders, providing a multifaceted approach to treatment in patients with coexisting conditions.

Mechanism of Action

The active ingredient in PENTRAL 400MG is Pregabalin, which functions by modulating the release of neurotransmitters in the brain. It binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. This binding inhibits excitatory neurotransmitter release, thereby reducing neuronal excitability. As a result, Pregabalin effectively decreases the frequency of seizures and alleviates neuropathic pain by dampening the overactive nerve signals that contribute to these conditions.

Pharmacological Properties

PENTRAL exhibits a rapid absorption profile, with peak plasma concentrations typically reached within 1 hour after oral administration. The bioavailability of Pregabalin is approximately 90%, and it is not significantly bound to plasma proteins. The drug is primarily eliminated through renal excretion, with a half-life of approximately 6 hours. This pharmacokinetic profile allows for flexible dosing schedules, making it suitable for various patient needs.

Contraindications

PENTRAL 400MG is contraindicated in patients with a known hypersensitivity to Pregabalin or any of the excipients in the formulation. Caution should be exercised when prescribing this medication to individuals with a history of substance abuse or dependence, as it may have potential for misuse. Additionally, patients with severe renal impairment should avoid this medication unless closely monitored by a healthcare provider.

Side Effects

Common side effects associated with PENTRAL 400MG include dizziness, drowsiness, dry mouth, and peripheral edema. Patients may also experience weight gain and difficulty concentrating. Serious adverse effects, although rare, can include allergic reactions, such as angioedema or anaphylaxis, and suicidal thoughts or behaviors. It is essential for patients to report any unusual symptoms or side effects to their healthcare provider promptly.

Dosage and Administration

The recommended initial dose of PENTRAL 400MG for adults typically starts at 150 mg per day, which may be divided into two or three doses. Depending on the patient’s response and tolerability, the dosage can be gradually increased to a maximum of 600 mg per day. For patients with renal impairment, dosage adjustments may be necessary to avoid accumulation and potential toxicity. It is crucial to follow the prescribing physician’s guidance regarding dosage and administration to ensure optimal therapeutic outcomes.

Interactions

PENTRAL 400MG may interact with other medications, leading to altered therapeutic effects or increased side effects. Notably, co-administration with central nervous system depressants, such as opioids or benzodiazepines, can enhance sedation and respiratory depression. Patients should inform their healthcare provider of all medications, supplements, and herbal products they are taking to avoid potential interactions. Furthermore, caution is advised when combining PENTRAL with medications that affect renal function, as this may necessitate dosage adjustments.

Precautions

Before initiating treatment with PENTRAL 400MG, healthcare providers should conduct a thorough assessment of the patient’s medical history, including any history of renal impairment, depression, or substance abuse. Patients should be monitored for signs of suicidal ideation, especially during the initial treatment phase or when doses are adjusted. Additionally, abrupt discontinuation of PENTRAL can lead to withdrawal symptoms; therefore, a gradual tapering of the dose is recommended when discontinuing therapy.

Clinical Studies

Clinical studies have demonstrated the efficacy of PENTRAL 400MG in reducing seizure frequency in patients with epilepsy and providing significant relief from neuropathic pain. A randomized, double-blind, placebo-controlled trial showed that Pregabalin significantly reduced the frequency of partial-onset seizures compared to placebo. Similarly, studies focusing on neuropathic pain indicated that patients treated with Pregabalin experienced substantial improvements in pain scores and overall quality of life. These findings support the use of PENTRAL as a valuable therapeutic option for managing these conditions.

Conclusion

PENTRAL 400MG is a versatile medication indicated for the management of epilepsy and neuropathic pain, with a well-established mechanism of action that targets excitatory neurotransmitter release. While it is generally well-tolerated, healthcare providers must remain vigilant regarding potential side effects and drug interactions. By adhering to recommended dosing guidelines and monitoring patient response, PENTRAL can provide significant therapeutic benefits for individuals suffering from these challenging conditions.